What is EDP Biotech?
EDP Biotech Corporation is an ISO 13485:2016 certified developer and manufacturer of in vitro diagnostics. Established in 2005, the company's core mission is to create and commercialize affordable diagnostic tools for the early detection of diseases in both human and animal populations. A key achievement for EDP Biotech is the development of ColoPlex, a multiplex biomarker assay designed for the early identification of colorectal cancer, a market segment the company has researched extensively.
How much funding has EDP Biotech raised?
EDP Biotech has raised a total of $76K across 1 funding round:
Debt
$76K
Debt (2021): $76K with participation from PPP
What's next for EDP Biotech?
With the recent influx of substantial expansion capital, EDP Biotech is poised for accelerated growth and market penetration. The company's focus on early disease detection, particularly in oncology with its ColoPlex assay, aligns with increasing global healthcare demands for preventative and diagnostic solutions. This strategic investment is expected to fuel further research and development, enhance manufacturing capabilities, and expand commercialization efforts, solidifying EDP Biotech's role as a key player in the diagnostic innovation landscape.
See full EDP Biotech company page
